Sun Pharmaceutical has completed its $4-billion merger with Ranbaxy, strengthening its position as the world's fifth largest specialty generic pharmaceutical company and top-ranking Indian pharma.

The combined entity will have operations in 65 countries, 47 manufacturing facilities across five continents, and will generate revenues of an estimated $4.2 billion. 

Sun says the move will enable it to significantly boost its R&D capabilities and global presence, as well as enhance its product portfolio and improve strategic flexibility.

Daiichi Sankyo becomes the second largest shareholder in Sun Pharma, having owned the majority of Ranbaxy pre-merger, and both companies will work together to leverage this relationship for global business growth, it was noted.